Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fampridine
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Biogen
Deal Size : $510.0 million
Deal Type : Termination
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
Details : Following termination, Acorda regains global commercialization rights to Fampyra, a prolonged-release formulation of fampridine (4-aminopyridine) for adults with multiple sclerosis.
Brand Name : Fampyra
Molecule Type : Small molecule
Upfront Cash : $110.0 million
January 11, 2024
Lead Product(s) : Fampridine
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Biogen
Deal Size : $510.0 million
Deal Type : Termination
LOOKING FOR A SUPPLIER?